AL
Azadyne Ltd
The startup develops RNA modification technologies that selectively enhance regulatory T cell (Treg) populations to treat autoimmune diseases. By targeting specific pathogenic immune pathways, the company provides a mechanism for effective management of autoimmune conditions.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$5.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops RNA modification technologies that selectively enhance regulatory T cell (Treg) populations to treat autoimmune diseases. By targeting specific pathogenic immune pathways, the company provides a mechanism for effective management of autoimmune conditions.